STOCK TITAN

Can-Fite BioPharma Ltd. (CANF) Stock News, May-Aug 2023

CANF NYSE

Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.

Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.30%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.10%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags

FAQ

What is the current stock price of Can-Fite BioPharma (CANF)?

Can-Fite BioPharma (CANF) last closed at $1.44.

What is the market cap of Can-Fite BioPharma (CANF)?

The market cap of Can-Fite BioPharma (CANF) is approximately $4.4M.